EUCTR2014-002351-26-IT进行中（未招募）1 期
A Phase 3, Randomized,Double-blind Study of Adjuvant Immunotherapy with Nivolumab versus Ipilimumab after Complete Resection of Stage IIIb/c or StageIV Melanoma in Subjects who are at High Risk for Recurrence - CheckMate 238: CHECKpoint pathway and nivoluMAb clinical Trial Evaluation 238
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 1,070
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Man and woman, 15 years or older (in some countries, only subjects aged 18 years or older will be recruited) -Completely
- •removed melanoma by surgery performed within 12 weeks of randomization -Stage IIIb/C or Stage IV before complete resection -
- •No previous anti-cancer treatment -Adequate function of the blood, kidney, and liver
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 870
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 190
排除标准
- •Ocular or uveal melanoma -History of carcinomatosis meningitis -History of auto-immune disease -Previous non-melanoma
- •cancers unless complete remission since 3 years -Treatment directed against the resected melanoma that is administrated after
- •the surgery -Postive testing for hepatitis B, hepatitis C, or known HIV
研究者
相似试验
进行中（未招募）
1 期
Study comparing nivolumab to ipilimumab in prevention of recurrence of melanoma after complete resection of stage IIIb/c or Stage IV melanomaHigh risk, completely resected Stage IIIb/c and IV melanoma subjects.MedDRA version: 19.1Level: LLTClassification code 10053571Term: MelanomaSystem Organ Class: 100000004864EUCTR2014-002351-26-IEBristol-Myers Squibb International Corporation1,070
进行中（未招募）
1 期
Study comparing nivolumab to ipilimumab in prevention of recurrence of melanoma after complete resection of stage IIIb/c or Stage IV melanomaHigh risk, completely resected Stage IIIb/c and IV melanoma subjects.MedDRA version: 21.1Level: LLTClassification code 10053571Term: MelanomaSystem Organ Class: 100000004864EUCTR2014-002351-26-GBBristol-Myers Squibb International Corporation1,070
进行中（未招募）
1 期
Study comparing nivolumab to ipilimumab in prevention of recurrence of melanoma after complete resection of stage IIIb/c or Stage IV melanomaEUCTR2014-002351-26-SEBristol-Myers Squibb International Corporation1,070
进行中（未招募）
1 期
Study comparing nivolumab to ipilimumab in prevention of recurrence of melanoma after complete resection of stage IIIb/c or Stage IV melanomaEUCTR2014-002351-26-NLBristol-Myers Squibb International Corporation1,070
进行中（未招募）
1 期
A Phase 3 Study of Nivolumab versus Placebo for Participants with Hepatocellular Cancer Who Are at High Risk of Recurrence after Hepatic Resection or AblatioHepatocellular CarcinomaEUCTR2017-002755-29-FRBristol-Myers Squibb International Corporation883